REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

19 فبراير 2025 15:05:00 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

29 يناير 2025 15:05:00 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

06 يناير 2025 15:05:00 بحسب Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

05 ديسمبر 2024 15:05:49 بحسب Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

03 ديسمبر 2024 21:38:42 بحسب Nasdaq GlobeNewswire

Revolution Medicines Announces Commencement of Public Offering of Common Stock

02 ديسمبر 2024 15:31:20 بحسب Nasdaq GlobeNewswire

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

02 ديسمبر 2024 06:30:02 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

27 نوفمبر 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

06 نوفمبر 2024 15:02:32 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

05 نوفمبر 2024 08:00:30 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

30 أكتوبر 2024 15:05:23 بحسب Nasdaq GlobeNewswire

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

25 أكتوبر 2024 03:15:00 بحسب Nasdaq GlobeNewswire

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

23 أكتوبر 2024 05:00:49 بحسب Nasdaq GlobeNewswire

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

21 أكتوبر 2024 15:05:39 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

07 أكتوبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

07 أغسطس 2024 15:05:41 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

31 يوليو 2024 15:05:11 بحسب Nasdaq GlobeNewswire

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

11 يوليو 2024 11:00:53 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

08 يوليو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

05 يونيو 2024 15:05:28 بحسب Nasdaq GlobeNewswire